IVI RMA North America, a major global fertility network, has confirmed an exclusive multi-year agreement with Sapyen to bring home-based male fertility testing into its clinical ecosystem.
The partnership aligns with increasing momentum across the fertility field to adopt remote diagnostic approaches capable of meeting laboratory-level scrutiny.
Historically, evaluating male fertility has required rapid delivery of samples to a laboratory—an approach that has limited accessibility and shaped the patient journey for generations.
Although interest in at-home testing has risen, many products still rely on predicted motility metrics or indirect scoring, offering ease but lacking the depth and accuracy needed for clinical guidance.
Sapyen’s model differs in a material way. The company’s patent-pending preservation liquid, SPX72™, preserves sperm viability for up to 72 hours, enabling samples collected at home to be transported to IVF-grade laboratories for analysis using WHO-aligned techniques.
Before formalizing the agreement, IVI RMA conducted internal validations of the technology within its andrology laboratories to assess whether results derived from stabilized samples could be interpreted within the organization’s established analytical frameworks.
According to both companies, the assessments showed that the stabilized samples produced data consistent with the standards IVI RMA applies across its network. For an organization known for its methodical approach to technology adoption, the outcome marks a significant development: a home-collection pathway capable of integrating into the same diagnostic system used for in-clinic patients.
“What interested us about this collaboration was not simply the shift to home collection but the opportunity to modernize part of the diagnostic pathway that has resisted change for decades. Our teams approached the evaluation the way we do with any technology that might influence patient care—methodically and with a focus on reproducibility,” said Glenn Proctor, Regional Vice President of IVI RMA North America. “Sapyen’s model fits within the integrity of our lab systems while giving patients a more flexible, less burdensome way to begin the fertility process. The partnership allows us to expand access in a way that still reflects the standards we hold ourselves to, and that combination is rare in this space.”
“IVI RMA’s evaluation was anchored in laboratory integrity, and that process guided the outcome,” said Ash Ramachandran, Chief Executive Officer of Sapyen. “But the significance of this partnership is larger than validation—it reflects a shift in how male fertility will be handled going forward. Clinics have been looking for a way to reconcile flexibility with accuracy; this collaboration shows that the two can finally coexist.”
The rollout will begin across IVI RMA’s West Coast clinics, with expansion planned as laboratory pathways and clinician training progress.
For an industry in which male diagnostics have historically lagged behind broader innovations, the collaboration offers a model for reconciling home-based access with the standards of clinical practice—a combination likely to influence how other networks approach male fertility testing.
